Abstract | BACKGROUND: OBJECTIVE: This analysis evaluated treatment practice patterns and LDL-C lowering for patients with CHD/CHD risk equivalent on statin monotherapy in a real-world practice setting in the United States. METHODS: In this retrospective, observational study, patients with CHD/CHD risk equivalent on statin therapy were identified during 2004 to 2008 in a US managed care database. Prescribing patterns and effect of switching from statin monotherapy to combination ezetimibe/simvastatin therapy vs uptitration to higher statin dose/potency level and no change from initial statin potency on LDL-C lowering were assessed. Percentage of change from baseline in LDL-C levels and odds ratios for LDL-C goal attainment were estimated with analyses of covariance and logistic regression. RESULTS: Of 27,919 eligible patients on statin therapy, 2671 (9.6%) switched to ezetimibe/ simvastatin therapy, 11,035 (39.5%) uptitrated statins, and 14,213 (50.9%) remained on the same statin monotherapy. LDL-C reduction from baseline and attainment of LDL-C <100 and <70 mg/dL were substantially greater for patients who switched to ezetimibe/ simvastatin therapy (-24.0%, 81.2%, and 35.2%, respectively) than for patients who titrated (-9.6%, 68.0%, and 18.4%, respectively) or remained on initial statin therapy (4.9%, 72.2%, and 23.7%, respectively). The odds ratios for attainment of LDL-C <100 and <70 mg/dL were also higher for patients who switched than for patients who uptitrated and had no therapy change than for patients who titrated vs no therapy change. Similarly, among a subgroup of patients not at LDL-C <100 mg/dL on baseline therapy, attainment of LDL-C <100 and <70 mg/dL was greater for patients who switched than for statin uptitration vs no change, as well as for patients who uptritrated statins vs no therapy change. CONCLUSION: In this study, LDL-C lowering and goal attainment rates improved substantially for patients with high-risk CHD on statin monotherapy who switched to combination ezetimibe/ statin or uptitrated their statin therapies; however, approximately one-third of these patients still did not attain the optional recommended LDL-C goal of <70 mg/dL. Moreover, these higher efficacy lipid-lowering therapies were infrequently prescribed, indicating the need for further assessment of barriers to LDL-C goal attainment in actual practice settings.
|
Authors | Peter P Toth, Joanne M Foody, Joanne E Tomassini, Shiva G Sajjan, Dena R Ramey, David R Neff, Andrew M Tershakovec, X Henry Hu, Kaan Tunceli |
Journal | Journal of clinical lipidology
(J Clin Lipidol)
2014 Jan-Feb
Vol. 8
Issue 1
Pg. 107-16
ISSN: 1933-2874 [Print] United States |
PMID | 24528691
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Azetidines
- Cholesterol, LDL
- Drug Combinations
- Ezetimibe, Simvastatin Drug Combination
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Simvastatin
|
Topics |
- Azetidines
(therapeutic use)
- Cardiovascular Diseases
(blood, drug therapy)
- Cholesterol, LDL
(blood)
- Drug Combinations
- Ezetimibe, Simvastatin Drug Combination
- Female
- Follow-Up Studies
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Male
- Middle Aged
- Odds Ratio
- Practice Patterns, Physicians'
- Simvastatin
(therapeutic use)
- Treatment Outcome
|